Cultivate Resiliency and Bypass Burnout

The FDA granted an accelerated approval to zanidatamab-hrii for previously treated, unresectable or metastatic HER2-positve biliary tract cancer.

In this special episode of The Vitals, we ring in the New Year 2024 by combing through 2023 FDA approvals.

Clinicians should consider a rapid taper approach for patients with cancer who exhibit repeated signs of opioid misuse, an expert said.

Beth Finley-Oliver, MSN, ARNP, AGNP-BC, recaps part of her presentation from the 2023 JADPRO meeting about caring for patients with high-risk multiple myeloma.

Bendamustine plus obinutuzumab outperformed historical data of bendamustine plus rituximab for patients with treatment naïve mantle cell lymphoma.

While bispecific antibodies tend to be well-tolerated for patients with multiple myeloma, there are still adverse effects clinicians should discuss with their patients.